A 25% reduced dose of gadobutrol for contrast-enhanced brain MRI is "noninferior" to a standard dose of gadoterate, according to a study published June 17 in the American Journal of Roentgenology.
The results could reduce contrast dose exposure in patients who undergo multiple exams with gadolinium-based contrast agents, said study corresponding author Dr. Jan Endrikat, PhD, of the University Medical School of Saarland in Germany in a statement released by the American Roentgen Ray Society (ARRS).
The study included 141 patients with known or suspected central nervous system conditions who underwent contrast-enhanced brain MRI with standard-dose gadoterate (0.1 mmol/kg); if a lesion was found, the patients underwent a second MRI with reduced-dose gadobutrol (0.075 mmol/kg) within 15 days.
"Comparison of reduced-dose gadobutrol and standard-dose gadoterate versus unenhanced imaging demonstrated noninferiority using 20% margin for three primary efficacy measures: subjective lesion enhancement, lesion border delineation, lesion internal morphology," the ARRS said.